Discover CME, tools, and guideline-focused education to improve your knowledge - and patient outcomes.
Partnering Through Treatment: Preparing for Immunotherapy in the Perioperative Setting
Jennifer Johnson, MD, PhD
Making the Right Moves in Metastatic CSPC: Intensification, Imaging, and Impact
Neeraj Agarwal, MD, FASCO
Rana McKay, MD
Putting It All Together: Challenges Addressed
David T. Rubin, MD
Ugonna Iroku, MD, MHS
IBD Beyond Symptoms: What Community GIs Need to Know
Higher Risk, Lowered Age: New Colorectal Cancer Screening Guidelines
John Russell, MD
Richard Wender, MD
Advancing Acromegaly Care: Diving Deeper Into Diagnosis, Guideline Application, and Emerging Therapies—A Fireside Chat With Expert Perspectives
June 15, 2026 Chicago, Illinois
Clear Skin, Clear Path: Transforming Psoriasis Care with Durable Biologic and Oral IL-23 Innovations
June 12, 2026 Denver, Colorado
The Future of HNSCC: Aligning Teams, Transforming Care
Ravindra Uppaluri, MD, PhD
Nancy Lee, MD, FASTRO
IBD Masterclass: Foundations of Pathophysiology and Targeted Therapy
Michael Dolinger, MD, MBA
Florence Odufalu, MD
Sharon Dudley-Brown, PhD, FNP-BC, FAAN, FAANP
Genetic Susceptibility in IBD: From Risk Genes to Clinical Impact
Retina Rumble: Debating Modern Treatment Options
Roger A. Goldberg, MD, MBA
Christina Y. Weng, MD, MBA, FASRS
Yasha S. Modi, MD
Redefining gMG Management: FcRn Antagonists and the New Era of Precision Neurology
September 30, 2026 Orlando, Florida
Treat. Target. Transform: Applying Treat-to-Target Principles in the Management of Generalized Myasthenia Gravis (gMG)
Christyn Edmundson, MD
Gil I. Wolfe MD, FAAN
Target Locked in gMG: Why T2T Matters
Before the Scalpel: Identifying Candidates for Perioperative Immunotherapy
Adam J. Luginbuhl, MD
Turning Evidence Into Action: Applying Perioperative Data to Real-World Practice
Beyond Biology: Environmental and Lifestyle Influences in IBD
Scorecards That Matter: Use MG-ADL, MG-MMT, QMG, QoL
Turning Flares Into Function: Flag Uncontrolled Disease
When to Begin FcRn: Initiation Criteria, Key Evidence
Targeting Inflammation in IBD: Localized vs Systemic Strategies
Shared Goals, Shared Gains: Align With Patient Preferences
The 2-Point Signal: Apply ≥2-Point Rule
FcRn: Same Class, Different Paths—Spot Agent Differentiators
Inside the 4 Hits: Targeting APRIL to Change the Course of IgAN
Richard Lafayette, MD, FACP
Dana Rizk, MD
Hong Zhang
Suzuki Yusuke, MD, PhD
Mechanism-Based Targeting: Why APRIL Matters in IgAN
Loading...
We're glad to see you're enjoying Prova Education… but how about a more personalized experience?
Press cancel to remain on Prova Education. Press the link below or the continue button to keep going.